Home/Filings/4/0001209191-11-062937

4//SEC Filing

SANDERLING V LTD PARTNERSHIP 4

Accession 0001209191-11-062937

CIK 0001235007other

View on SEC.gov Company Profile

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 8:28 PM ET

Size

31.5 KB

Accession

0001209191-11-062937

Insider Transaction Report

Form 4

Period: 2011-12-20

ENDOCYTE INCECYT

Sanderling Venture Partners V Co Investment Fund, LP

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304

SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417

SANDERLING V LTD PARTNERSHIP

10% Owner

Transactions

Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828

Sanderling VI Beteiligungs GmbH & Co KG

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434

Sanderling Venture Partners V, LP

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170

SANDERLING V BETEILIGUNGS GMBH & CO KG

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Partnership)
113,315

SANDERLING V BIOMEDICAL LP

10% Owner

Transactions

Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434

Sanderling V Strategic Exit Fund LP

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417

Sanderling Venture Partners VI Co Investment Fund LP

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434
Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828

Sanderling VI Limited Partnership

10% Owner

Transactions

Purchase
Common Stock
2011-12-20$3.20/sh+217,800$696,960→ 653,661 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)
Purchase
Common Stock
2011-12-21$3.16/sh+217,800$688,248→ 871,461 total(indirect: By Sanderling Venture Partners VI Co-Investment Fund, L.P,)

Holdings

Common Stock
(indirect: By Sanderling V Strategic Exit Fund, L.P.)
785,417
Common Stock
(indirect: By Sanderling Venture Partners V, L.P.)
1,017,304
Common Stock
(indirect: By Sanderling Venture Partners V Co-Investment Fund, L.P.)
267,491
Common Stock
(indirect: By Sanderling V Biomedical, L.P.)
249,148
Common Stock
(indirect: By Sanderling V Beteiligungs GmbH & Co. KG)
100,828
Common Stock
(indirect: By Sanderling V Biomedical Co-Investment Fund, L.P.)
162,170
Common Stock
(indirect: By Partnership)
113,315
Common Stock
(indirect: By Partnership)
10,049
Common Stock
(indirect: By Sanderling VI Beteiligungs GmbH & Co. KG)
8,434

Footnotes (5)

[F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
[F3]Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling VI Limited Partnership and Sanderling V Strategic Exit Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling V Strategic Exit Fund, L.P. and Sanderling VI Limited Partnership.
[F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]Fred Middleton is a managing director of Middleton, McNeil & Mills Associate V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners V Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares of record by Sanderling Venture Partners V Co-Investment Fund, L.P.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

ENDOCYTE INC

CIK 0001235007

→

Entity typeother

Related Parties

filerCIK 0001267960

Filing Metadata

Form type: 4
Filed: Dec 21, 7:00 PM ET
Accepted: Dec 22, 8:28 PM ET
Size: 31.5 KB

View on SEC.gov